Danaher Total Cost of Revenue decreased by 17.8% to $2.36B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $2.23B to $2.36B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows relatively stable performance with a 1.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.82B | $2.87B | $1.27B | $2.98B | $3.03B | $3.08B | $1.36B | $2.29B | $2.59B | $2.35B | $2.63B | $2.31B | $2.32B | $2.40B | $2.65B | $2.23B | $2.41B | $2.53B | $2.87B | $2.36B |
| QoQ Change | — | +1.7% | -55.9% | +135.4% | +1.6% | +1.6% | -55.7% | +67.8% | +13.4% | -9.4% | +11.8% | -12.1% | +0.3% | +3.5% | +10.5% | -15.8% | +8.2% | +4.8% | +13.5% | -17.8% |
| YoY Change | — | — | — | — | +7.4% | +7.3% | +7.6% | -23.3% | -14.4% | -23.7% | +92.7% | +1.0% | -10.8% | +2.0% | +0.8% | -3.4% | +4.2% | +5.5% | +8.5% | +5.8% |